Genentech Signs a Development and Commercialization Agreement with Xencor for its IL-15 & XmAb24306 Programs

 Genentech Signs a Development and Commercialization Agreement with Xencor for its IL-15 & XmAb24306 Programs

Genentech Signs a Development and Commercialization Agreement with Xencor for its IL-15 & XmAb24306 Programs

Shots:

  • Xencor to receive $120M upfront, $160M milestones for XmAb24306 program and $180M for IL-15 candidate. Genentech to get worldwide commercialization rights for XmAb24306 & IL-15 program, with Xencor has an option for its co-promotion in the US, sharing equal cost/profit
  • The companies will collaborate for a two-year research program for discovering IL-15 drug candidates, with its expected closure in H1’19
  • XmAb24306 is an IL-15/IL-15Rα cytokine, developed using Xencor’s Fc domain and Xtend Fc technology evaluated in preclinical trials for multiple cancer

Click here read full press release/ article | Ref: PRNewswire | Image: Fatherly

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post